2024-02-15 11:35:43 ET
Summary
- Liquidia Corporation shares rallied over 80% after an appeals court invalidated the patent of rival United Therapeutics, potentially paving the way for approval of its PAH and PH-ILD medication Yutrepia.
- However, the FDA recently extended the original action data on that marketing application late in January.
- The company has faced legal battles with United Therapeutics but still should be able to gain full FDA approval for Yutrepia, hopefully in the first half of 2024.
- The complicated tale around Liquidia is highlighted in the paragraphs below.
Loyalty to country ALWAYS. Loyalty to government, when it deserves it .”? Mark Twain.
Read the full article on Seeking Alpha
For further details see:
Liquidia Corporation: A Complicated Tale